Literature DB >> 23607945

[Risk factors for parenteral nutrition-associated cholestasis in preterm infants].

Yan-Hua Li1, Xin-Li Wang.   

Abstract

OBJECTIVE: To investigate risk factors for parenteral nutrition-associated cholestasis (PNAC) in preterm infants.
METHODS: A retrospective case-control study was performed on 244 preterm infants who received parenteral nutrition (PN) for over 14 days from January 2000 to October 2011.
RESULTS: Compared with those without PNAC (n=221), preterm infants with PNAC (n=23) had a longer total duration of PN, a higher total amino acid intake, a higher total lipid intake, a higher maximum daily amino acid intake, a higher maximum daily lipid intake, a higher intravenous calorie intake on the 14th day of PN, a lower birth weight and higher incidence rates of neonatal infection and anemia. Compared with those with PNAC, preterm infants without PNAC who showed a higher total amino acid intake also had a higher total lipid intake, a longer total duration of PN, a higher rate of mechanical ventilation and a lower gestational age. The preterm infants without PNAC who showed a higher total lipid intake also had a lower gestational age. Preterm infants without PNAC who showed a longer total duration of PN also had a lower gestational age.
CONCLUSIONS: Total duration of PN, total amino acid intake, maximum daily amino acid intake, total lipid intake, maximum daily lipid intake, intravenous calorie intake on the 14th day of PN, low birth weight, and neonatal infection and anemia are the risk factors for PNAC. Other risk factors need further investigation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23607945

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  1 in total

1.  The Effect of Fish Oil-Based Lipid Emulsion and Soybean Oil-Based Lipid Emulsion on Cholestasis Associated with Long-Term Parenteral Nutrition in Premature Infants.

Authors:  Leilei Wang; Jing Zhang; Jiejin Gao; Yan Qian; Ya Ling
Journal:  Gastroenterol Res Pract       Date:  2016-03-24       Impact factor: 2.260

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.